-
Product Insights
Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Severe Acute Respiratory Syndrome (SARS) - Drugs In Development, 2023’, provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Dengue Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Dengue Fever - Drugs In Development, 2023’, provides an overview of the Dengue Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Zika Virus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Zika Virus Infections - Drugs In Development, 2023’, provides an overview of the Zika Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hepatitis C – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis C - Drugs In Development, 2023’, provides an overview of the Hepatitis C pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Company Profile
NewBiotron Ltd – Company Profile
Biotron Ltd (Biotron) is a clinical stage biotechnology company that develops novel small molecule antiviral therapeutics for the treatment of infectious diseases such as hepatitis C virus (HCV) and HIV-1. Biotron’s core focus is to design and develop drugs that target a new class of viral proteins (viroporins). The company’s lead drug candidate, BIT225 is in Phase II clinical trials for the treatment of both HIV-1. Biotron also has other preclinical programs targeting infectious diseases such as dengue, Zika and...
Add to Basket -
Product Insights
Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dengue Fever Pipeline Drugs Market Report Overview Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style. The dengue fever pipeline...
-
Product Insights
Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Zika Virus Infections Pipeline Drugs Market Report Overview Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications. The Zika Virus Infections pipeline drugs market research report provides comprehensive information on the Zika...
-
Product Insights
Immunochemistry Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Spot test kits intended generally for rapid diagnosis, with immediate results, through immuno assays. Some of the tests carried out using immunochemistry rapid test include rabies virus test, allergenic food proteins, and enteric infection. The immunochemistry rapid tests and POC pipeline market research report provides comprehensive information about the immunochemistry rapid tests and POC pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BIT-225
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry BIT-225 Drug Details BIT-225 is under development for the treatment of chronic hepatitis C...